Glaxosmithkline | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Amgen USD 8.81B 3.16B 2025-03
AstraZeneca USD 5.23B 258M 2025-03
Aurora Cannabis CAD 108.71M 23.79M 2024-12
Bausch Health Companies USD 1.13B 47M 2025-03
Bristol-Myers Squibb USD 10.88B 529M 2025-03
Canopy Growth CAD 16.31M 69.8M 2024-12
Corcept Therapeutics USD 89.82M 37.85M 2025-03
Drreddys Laboratories INR 1.1B 743M 2024-12
Eli Lilly USD 3.09B 175.1M 2025-03
GlaxoSmithKline GBP 4.46B 594M 2025-03
Glaxosmithkline GBP 3.87B 678M 2024-12
Indivior 372M 53M 2025-03
J&J USD 38.47B 32.35B 2025-03
Merck USD 8.63B 4.61B 2025-03
Novartis USD 8.87B 4.74B 2024-12
Pacira USD 283.61M 6.84M 2025-03
Perrigo USD 409.9M 148.9M 2025-03
Pfizer USD 1.43B 387M 2025-03
Prestige Brands USD 97.88M 47.01M 2025-03
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 7.99B 550M 2025-03
Supernus Pharmaceuticals USD 69.33M 37.66M 2024-12
Takeda JPY 385.11B 109.01B 2025-03
Teva Pharmaceutical Industries USD 1.7B 1.6B 2025-03
Zoetis USD 1.72B 264M 2025-03



Glaxosmithkline Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - May 2025.